mtmt
The Hungarian Scientific Bibliography
XML
JSON
Public search
Magyarul
Citations
/
Citings
Rewired Metabolism Caused by the Oncogenic Deregulation of MYC as an Attractive Therapeutic Target in Cancers
Vízkeleti, L. [Vízkeleti, Laura (molekuláris bioló...), author] Bioinformatika Tanszék (SU / FM / I)
;
Spisák, S. ✉ [Spisák, Sándor (Molekuláris genetika), author] Institute of Enzymology (RCNS)
English Survey paper (Journal Article) Scientific
Published:
CELLS 2073-4409
12
(13)
Paper: 1745
, 25 p.
2023
SJR Scopus - Biochemistry, Genetics and Molecular Biology (miscellaneous): Q1
Identifiers
MTMT: 34075115
DOI:
10.3390/cells12131745
WoS:
001028514400001
Scopus:
85164715646
PubMed:
37443779
Fundings:
(K-142835) Funder: NKFI
MYC is one of the most deregulated oncogenes on multiple levels in cancer. As a node transcription factor, MYC plays a diverse regulatory role in many cellular processes, including cell cycle and metabolism, both in physiological and pathological conditions. The relentless growth and proliferation of tumor cells lead to an insatiable demand for energy and nutrients, which requires the rewiring of cellular metabolism. As MYC can orchestrate all aspects of cellular metabolism, its altered regulation plays a central role in these processes, such as the Warburg effect, and is a well-established hallmark of cancer development. However, our current knowledge of MYC suggests that its spatial- and concentration-dependent contribution to tumorigenesis depends more on changes in the global or relative expression of target genes. As the direct targeting of MYC is proven to be challenging due to its relatively high toxicity, understanding its underlying regulatory mechanisms is essential for the development of tumor-selective targeted therapies. The aim of this review is to comprehensively summarize the diverse forms of MYC oncogenic deregulation, including DNA-, transcriptional- and post-translational level alterations, and their consequences for cellular metabolism. Furthermore, we also review the currently available and potentially attractive therapeutic options that exploit the vulnerability arising from the metabolic rearrangement of MYC-driven tumors. © 2023 by the authors.
Cited in (3)
Citing (4)
Citation styles:
IEEE
ACM
APA
Chicago
Harvard
CSL
Copy
Print
2025-04-24 16:24
×
Export list as bibliography
Citation styles:
IEEE
ACM
APA
Chicago
Harvard
Print
Copy